[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","commit":"91a4bba51c","date":"2026-09-10","author":"Jude Gomila","message":"Fourteen orphan products now linked from their targets and cancers (ALK, EGFR, ROS1, ER, FOLR1 inhibitors and tracers; myeloma, prostate, gl","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"drugs","after":"[\"elotuzumab\", \"panobinostat\", \"sipuleucel-t\", \"fluciclovine-f18\", \"aminolevulinic-acid-gleolan\", \"pegulicianine\"]"}]},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"tldr","before":"\"A plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC.\"","after":"\"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC.\""}]},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Newly diagnosed\", approach: \"Dara-VRd ± ASCT → lenalidomide maintenance.\", refs: [\"whole-body-mri\"] },\n      { setting: \"Relapsed\", approach: \"CAR-T or bispecific; belantamab combinations; sequenci...","after":"[\n      { setting: \"Newly diagnosed\", approach: \"Dara-VRd ± ASCT → lenalidomide maintenance.\", refs: [\"whole-body-mri\"], guideline: { version: \"NCCN Guidelines: Multiple Myeloma\", url: \"https://www.nccn.org/guidelines..."}]}]